Contemporary indications and therapeutic implications for digoxin use

American Journal of Therapeutics

Volumn 18, Issue 4, 2011, Pages 280-287

  Mittal, Mayank K ^a   Chockalingam, Priya ^b   Chockalingam, Anand ^a,c  

^a University of Missouri   (United States)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

atrial fibrillation; cardiovascular diseases; digoxin; disease management; heart failure

Indexed keywords

AMIODARONE; ANTACID AGENT; CALCIUM; COLESTIPOL; COLESTYRAMINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIURETIC AGENT; ERYTHROMYCIN; METOCLOPRAMIDE; NEOMYCIN; OMEPRAZOLE; PROPAFENONE; QUINIDINE; RIFAMPICIN; SUXAMETHONIUM; TETRACYCLINE; VERAPAMIL;

ACUTE DISEASE; ACUTE HEART FAILURE; CARDIOMYOPATHY; CHRONIC DISEASE; CONGENITAL HEART DISEASE; DIASTOLIC HEART FAILURE; DISEASE CLASSIFICATION; DRUG ABSORPTION; DRUG EXCRETION; DRUG POTENTIATION; DRUG SAFETY; DRUG USE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTILITY; HEART RATE; HEMODYNAMICS; HUMAN; KIDNEY FAILURE; OUTCOME ASSESSMENT; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PATIENT CARE; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; REVIEW; SYSTEMATIC REVIEW; TACHYCARDIA; TIME; TREATMENT INDICATION; UNITED KINGDOM; UNITED STATES; VALVULAR HEART DISEASE;

CARDIOTONIC AGENTS; DIGOXIN; HEART; HEART DISEASES; HUMANS; HYPERTENSION, PULMONARY; VASCULAR DISEASES;

EID: 79960562362     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181c6c0d2     Document Type: Review

References (43)

1. Hunt SA, Abraham WT, Chin MH, et al. Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53:E1-E90.
2. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant. 1994;13:S107-S112. (Pubitemid 24249591)
3. Association AH. Heart Disease and Stroke Statistics\- 2007 Update. Dallas, TX: American Heart Association; 2007: 21-23. Available at: http://www.americanheart.org/ downloadable/heart/1166712318459HS- StatsInsideText.pdf.
4. Withering W. An Account of the Foxgolve and Some of its Medical Uses, With Practical Remarks on Dropsy, and Other Disease. Vol I. New York: Henry Schuman, Drover Publication; 1941.
5. Gheorghiade M, Harinstein ME, Filippatos GS. Digoxin for the treatment of chronic and acute heart failure syndromes. Acute Card Care. 2009;11:83-87.
6. Newton GE, Tong JH, Schofield AM, et al. Digoxin reduces cardiac sympathetic activity in severe congestive heart failure. J Am Coll Cardiol. 1996;28:155-161. (Pubitemid 26266635)
7. Gheorghiade M, Hall VB, Jacobsen G, et al. Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors. Circulation. 1995;92:1801-1807.
8. Gheorghiade M, Adams KF Jr, Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation. 004; 109:2959-2964.
9. Smith TW. Pharmacokinetics, bioavailability and serum levels of cardiac glycosides. J Am Coll Cardiol. 1985; 5(Suppl A):43A-50A. (Pubitemid 15051732)
10. Gottlieb SS, Rogowski AC, Weinberg M, et al. Elevated concentrations of endogenous ouabain in patients with congestive heart failure. Circulation. 1992;86:420-425.
11. de The H, Devynck MA, Rosenfeld J, et al. Plasma sodium pump inhibitor in essential hypertension and normoten-sive subjects with hypertensive heredity. J Cardiovasc Pharmacol. 1984;6(Suppl 1):S49-S54. (Pubitemid 14123969)
12. Mahon N, McKenna WJ. Digoxin-like immunoreactive substances in hypertrophic cardiomyopathy. Eur Heart J. 1034;21:1034-1036.
13. Hayashi T, Ijiri Y, Toko H, et al. Increased digitalis-like immunoreactive substances in patients with hypertrophic cardiomyopathy. Eur HeartJ. 2000;21:296-305. (Pubitemid 30148301)
14. Bagrov A, Fedorova OV, Maslova MN, et al. Endogenous plasma Na,K-ATPase inhibitory activity and digoxin like immunoreactivity after acute myocardial infarction. Cardiovasc Res. 1991;25:371-377.
15. Pudek MR, Seccombe DW, Whitfield MF, et al. Digoxin-like immunoreactivity in premature and full-term infants not receiving digoxin therapy N Engl J Med. 1983;308: 904-905. (Pubitemid 13116551)
16. Smith TW, Antman EM, Friedman PL, et al. Digitalis glycosides: mechanisms and manifestations of toxicity. Part I. Prog Cardiovasc Dis. 1984;26:413-458. (Pubitemid 14170170)
17. Antman EM, Smith TW. Digitalis toxicity. Annu Rev Med. 1985;36:357-367.
18. Gheorghiade M, van Veldhuisen DJ, Colucci WS. Contemporary use of digoxin in the management of cardiovascular disorders. Circulation. 2006;113:2556-2564. (Pubitemid 43948035)
19. Management of chronic heart failure in adults in primary and secondary care 2003; The National Institute for Health and Clinical Exellence chronic heart failure guidelines. Available at: http://www.nice.org. uk/nicemedia/pdf/Full-HF-Guideline.pdf. Accessed October 9, 2009.
20. Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur HeartJ. 2006;27:178-186. (Pubitemid 43069034)
21. Adams KF Jr, Gheorghiade M, Uretsky BF, et al. Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol. 2002;39:946-953. (Pubitemid 34234114)
22. Ahmed A, Rich MW, Fleg JL, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006;114:397-403 (Pubitemid 44264821)
23. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med. 1997;336:525-533.
24. Rationale, design, implementation, and baseline charac-teristics of patients in the DIG trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure. Control Clin Trials. 1996;17:77-97.
25. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardi-ology Committee for Practice Guidelines (Writing Com-mittee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Associ-ation and the Heart Rhythm Society. Circulation. 2006;114: E257-E354.
26. Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias-executive summary. a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. J Am Coll Cardiol. 2003;42:1493-1531.
27. Aubier M, Murciano D, Viires N, et al. Effects of digoxin on diaphragmatic strength generation in patients with chronic obstructive pulmonary disease during acute respiratory failure. Am Rev Respir Dis. 1987;135:544-548. (Pubitemid 17041580)
28. Brown SE, Pakron FJ, Milne N, et al. Effects of digoxin on exercise capacity and right ventricular function during exercise in chronic airflow obstruction. Chest. 1984;85: 187-191. (Pubitemid 14192502)
29. Rich S, Seidlitz M, Dodin E, et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest. 1998;114:787-792. (Pubitemid 28433741)
30. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115:343-349.
31. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/ AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association devel-oped in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53:1573-1619.
32. Beiser GD, Epstein SE, Stampfer M, et al. Studies on digitalis. XVII. Effects of ouabain on the hemodynamic response to exercise in patients with mitral stenosis in normal sinus rhythm. N Engl J Med. 1968;278:131-137.
33. Bonow RO, Carabello BA, Chatterjee K, et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiogra-phy and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;52:E1-E142.
34. Kantor PF, Mertens LL. Clinical practice: heart failure in children. Part I: clinical evaluation, diagnostic testing, and initial medical management. Eur J Pediatr. 2010;169: 269-279.
35. Fenton M, Burch M. Understanding chronic heart failure. Arch Dis Child. 2007;92:812-816. (Pubitemid 47372538)
36. Patel D, Cuneo B, Viesca R, et al. Digoxin for the treatment of fetal congestive heart failure with sinus rhythm assessed by cardiovascular profile score. J Matern Fetal Neonatal Med. 2008;21:477-482. (Pubitemid 352000666)
37. Salerno JC, Seslar SP. Supraventricular tachycardia. Arch Pediatr Adolesc Med. 2009;163:268-274.
38. Hsich EM, Pina IL. Heart failure in women: a need for prospective data. J Am Coll Cardiol. 2009;54:491-498.
39. Rathore SS, Wang Y, Krumholz HM. Sex-based differ-ences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002;347:1403-1411. (Pubitemid 35239712)
40. Adams KF Jr, Patterson JH, Gattis WA, et al. Relationship of serum digoxin concentration to mortality and mor-bidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol. 2005;46: 497-504. (Pubitemid 41040292)
41. Joglar JA, Page RL. Treatment of cardiac arrhythmias during pregnancy: safety considerations. Drug Saf. 1999;20:85-94. (Pubitemid 29041617)
42. Ahmed A, Pitt B, Rahimtoola SH, et al. Effects of digoxin at low serum concentrations on mortality and hospital-ization in heart failure: a propensity-matched study of the DIG trial. Int J Cardiol. 2008;123:138-146. (Pubitemid 350258580)
43. Fonarow GC, Abraham WT, Albert NM, et al. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am Heart J. 2004;148:43-51. (Pubitemid 38900479)